Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Other financing activities (2021 - 2025)

Historic Other financing activities for Molecular Partners Ag (MOLN) over the last 5 years, with Q3 2025 value amounting to $485290.1.

  • Molecular Partners Ag's Other financing activities rose 1407.44% to $485290.1 in Q3 2025 from the same period last year, while for Sep 2025 it was $485290.1, marking a year-over-year increase of 1407.44%. This contributed to the annual value of $437488.0 for FY2024, which is 616.53% up from last year.
  • Per Molecular Partners Ag's latest filing, its Other financing activities stood at $485290.1 for Q3 2025, which was up 1407.44% from $467615.4 recorded in Q2 2025.
  • Molecular Partners Ag's Other financing activities' 5-year high stood at $406.4 million during Q2 2024, with a 5-year trough of $371922.5 in Q3 2022.
  • In the last 5 years, Molecular Partners Ag's Other financing activities had a median value of $422587.6 in 2024 and averaged $74.2 million.
  • Data for Molecular Partners Ag's Other financing activities shows a peak YoY increase of 1407.44% (in 2025) and a maximum YoY decrease of 9988.49% (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Molecular Partners Ag's Other financing activities stood at $385009.1 in 2021, then decreased by 2.85% to $374023.1 in 2022, then grew by 10.18% to $412081.9 in 2023, then increased by 6.62% to $439343.2 in 2024, then rose by 10.46% to $485290.1 in 2025.
  • Its Other financing activities was $485290.1 in Q3 2025, compared to $467615.4 in Q2 2025 and $429347.6 in Q1 2025.